Table 2.

Prospective analyses of the association of Mediterranean Diet Score on risk of graft failure, kidney function decline, and graft loss per two-point increment

	Primary End Point		Secondary End Points
	Graft Failure		Kidney Function Decline		Graft Loss
No. of Events	76		119		181
Model	Hazard Ratio (95% CI)	P Value	Hazard Ratio (95% CI)	P Value	Hazard Ratio (95% CI)	P Value
Crude	0.76 (0.58 to 0.98)	0.04	0.76 (0.62 to 0.93)	0.009	0.78 (0.66 to 0.92)	0.004
Model 1	0.76 (0.58 to 0.99)	0.04	0.76 (0.61 to 0.93)	0.008	0.78 (0.66 to 0.92)	0.003
Model 2	0.68 (0.50 to 0.91)	0.01	0.67 (0.54 to 0.83)	<0.001	0.72 (0.61 to 0.86)	<0.001
Model 3	0.68 (0.50 to 0.91)	0.01	0.68 (0.55 to 0.85)	0.001	0.74 (0.63 to 0.88)	0.001
Model 4	0.66 (0.49 to 0.90)	0.008	0.67 (0.54 to 0.84)	0.001	0.73 (0.61 to 0.87)	<0.001
Model 5	0.67 (0.50 to 0.91)	0.009	0.68 (0.55 to 0.86)	0.001	0.74 (0.62 to 0.88)	0.001
Model 6	0.64 (0.47 to 0.88)	0.005	0.68 (0.54 to 0.85)	0.001	0.72 (0.60 to 0.86)	<0.001
Model 7	0.68 (0.50 to 0.92)	0.01	0.70 (0.56 to 0.88)	0.003	0.73 (0.61 to 0.87)	0.001

Model 1: Mediterranean Diet Score, age, sex, and body surface area. Model 2: model 1 plus primary kidney disease, eGFR, 24-hour protein excretion, and time since transplantation. Model 3: model 2 plus total HLA mismatches, living donor kidney status, and pre-emptive transplantation. Model 4: model 3 plus history of acute rejection, cytomegalovirus infection, and hepatitis C status. Model 5: model 3 plus calcineurin inhibitor use, proliferation inhibitor use, and prednisolone use. Model 6: model 3 plus diabetes, systolic BP, cardiovascular history, ACE inhibitor, angiotensin II antagonist, and thiazide diuretic. Model 7: model 3 plus smoking status, physical activity (SQUASH score), energy intake, protein intake, and weight gain 1 year after baseline. 95% CI, 95% confidence interval; ACE, angiotensin-converting enzyme; SQUASH, Short Questionnaire to Assess Health-Enhancing Physical Activity.